Diaceutics PLC (FRA:7DC)

Diaceutics Statistics

Total Valuation

Diaceutics has a market cap or net worth of EUR 140.09 million. The enterprise value is 129.56 million.

Market Cap	140.09M
Enterprise Value	129.56M

Important Dates

The next estimated earnings date is Wednesday, December 24, 2025.

Earnings Date	Dec 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	84.64M
Shares Outstanding	n/a
Shares Change (YoY)	+0.19%
Shares Change (QoQ)	+0.10%
Owned by Insiders (%)	23.42%
Owned by Institutions (%)	48.67%
Float	49.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	55.35
PS Ratio	3.49
PB Ratio	3.22
P/TBV Ratio	5.49
P/FCF Ratio	12,008.01
P/OCF Ratio	1,154.62
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 74.59, with an EV/FCF ratio of 11,106.05.

EV / Earnings	-73.07
EV / Sales	3.31
EV / EBITDA	74.59
EV / EBIT	n/a
EV / FCF	11,106.05

Financial Position

The company has a current ratio of 3.96, with a Debt / Equity ratio of 0.03.

Current Ratio	3.96
Quick Ratio	3.66
Debt / Equity	0.03
Debt / EBITDA	0.74
Debt / FCF	113.40
Interest Coverage	-37.25

Financial Efficiency

Return on equity (ROE) is -4.00% and return on invested capital (ROIC) is -3.27%.

Return on Equity (ROE)	-4.00%
Return on Assets (ROA)	-2.85%
Return on Invested Capital (ROIC)	-3.27%
Return on Capital Employed (ROCE)	-5.36%
Revenue Per Employee	188,419
Profits Per Employee	-8,325
Employee Count	199
Asset Turnover	0.77
Inventory Turnover	n/a

Taxes

Income Tax	-159,824
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +32.12% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+32.12%
50-Day Moving Average	1.70
200-Day Moving Average	1.52
Relative Strength Index (RSI)	30.22
Average Volume (20 Days)	122

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Diaceutics had revenue of EUR 40.13 million and -1.77 million in losses. Loss per share was -0.02.

Revenue	40.13M
Gross Profit	34.56M
Operating Income	-2.39M
Pretax Income	-1.93M
Net Income	-1.77M
EBITDA	1.55M
EBIT	-2.39M
Loss Per Share	-0.02

Balance Sheet

The company has 12.11 million in cash and 1.32 million in debt, giving a net cash position of 10.79 million.

Cash & Cash Equivalents	12.11M
Total Debt	1.32M
Net Cash	10.79M
Net Cash Per Share	n/a
Equity (Book Value)	43.45M
Book Value Per Share	0.51
Working Capital	21.33M

Cash Flow

In the last 12 months, operating cash flow was 121,326 and capital expenditures -109,660, giving a free cash flow of 11,666.

Operating Cash Flow	121,326
Capital Expenditures	-109,660
Free Cash Flow	11,666
FCF Per Share	n/a

Margins

Gross margin is 86.12%, with operating and profit margins of -5.96% and -4.42%.

Gross Margin	86.12%
Operating Margin	-5.96%
Pretax Margin	-4.82%
Profit Margin	-4.42%
EBITDA Margin	3.85%
EBIT Margin	-5.96%
FCF Margin	0.03%

Dividends & Yields

Diaceutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.19%
Shareholder Yield	-0.19%
Earnings Yield	-1.27%
FCF Yield	0.01%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Diaceutics has an Altman Z-Score of 11.4 and a Piotroski F-Score of 4.

Altman Z-Score	11.4
Piotroski F-Score	4